Assessment of CD52 Expression in Double-Hit and Double-Expressor Lymphomas: Implications for Clinical Trial Eligibility
Jeffrey W. Craig(Rockefeller University), Olga Pozdnyakova(Memorial Medical Center), Michael J. Mina(Harvard College Observatory), Jennifer L. Crombie(Dana-Farber Cancer Institute), Geraldine S. Pinkus(Brigham and Women's Hospital), Ann S. LaCasce(Otsuka (Japan)), David M. Weinstock(Broad Institute)
Cited by 0
Related Papers
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
|Science|2022|2k
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
|Nature|2000|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716